Adding Immunotherapy to Chemo and Bevacizumab Extends Survival in Recurrent Cervical Cancer
A retrospective Chinese study finds that adding the PD-1 inhibitor tislelizumab to paclitaxel-carboplatin chemotherapy and bevacizumab significantly improves response rates, ...
